In addition, miR-300 can down-regulate the expression of CDKN1A in melanoma cells by regulating TP53 and GADD45B, thus promoting the transition of the cell cycle from the G1/S phase to the G2 phase and accelerating tumor growth. Here, TP53 is linked to neoplasm.